Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Paolini

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Alzheimer'S Research & Therapy|September 30, 2020
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?Giovanni Bellomo, Samuela Cataldi, Silvia Paciotti, et al.
Frontiers in Bioscience (Landmark Edition)|December 3, 2021
Seed amplification assays for diagnosing synucleinopathies: the issue of influencing factorsGiovanni Bellomo, Silvia Paciotti, Leonardo Gatticchi, et al.
Neurobiology of Disease|December 24, 2025
Cerebrospinal fluid α-synuclein seed amplification assay positivity is associated with increased plasma neurofilament light chain in Alzheimer's diseaseGiovanni Bellomo, Andrea Toja, Lorenzo Gaetani, et al.
Diagnostics (Basel, Switzerland)|December 1, 2020
A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy BodiesGiovanni Bellomo, Federico Paolini Paoletti, Elena Chipi, et al.
Trends in Pharmacological Sciences|October 31, 2020
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for TreatmentLorenzo Gaetani, Federico Paolini Paoletti, Giovanni Bellomo, et al.
Journal of Alzheimer'S Disease : JAD|July 5, 2022
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical ValidationAnna Lidia Wojdała, Davide Chiasserini, Giovanni Bellomo, et al.
Neurology|August 1, 2022
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way ForwardGiovanni Bellomo, Chiara Maria Giulia De Luca, Federico Paolini Paoletti, et al.
Behavioural Neurology|March 7, 2022
An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement DisordersNicola Tambasco, Pasquale Nigro, Andrea Chiappiniello, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 5, 2022
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as BiomarkersLorenzo Barba, Federico Paolini Paoletti, Giovanni Bellomo, et al.
Alzheimer'S Research & Therapy|May 22, 2025
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer's disease and Parkinson's diseaseLorenzo Gaetani, Giovanni Bellomo, Davide Chiasserini, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Alzheimer'S Research & Therapy|September 30, 2020
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?Giovanni Bellomo, Samuela Cataldi, Silvia Paciotti, et al.
Frontiers in Bioscience (Landmark Edition)|December 3, 2021
Seed amplification assays for diagnosing synucleinopathies: the issue of influencing factorsGiovanni Bellomo, Silvia Paciotti, Leonardo Gatticchi, et al.
Neurobiology of Disease|December 24, 2025
Cerebrospinal fluid α-synuclein seed amplification assay positivity is associated with increased plasma neurofilament light chain in Alzheimer's diseaseGiovanni Bellomo, Andrea Toja, Lorenzo Gaetani, et al.
Diagnostics (Basel, Switzerland)|December 1, 2020
A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy BodiesGiovanni Bellomo, Federico Paolini Paoletti, Elena Chipi, et al.
Trends in Pharmacological Sciences|October 31, 2020
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for TreatmentLorenzo Gaetani, Federico Paolini Paoletti, Giovanni Bellomo, et al.
Journal of Alzheimer'S Disease : JAD|July 5, 2022
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical ValidationAnna Lidia Wojdała, Davide Chiasserini, Giovanni Bellomo, et al.
Neurology|August 1, 2022
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way ForwardGiovanni Bellomo, Chiara Maria Giulia De Luca, Federico Paolini Paoletti, et al.
Behavioural Neurology|March 7, 2022
An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement DisordersNicola Tambasco, Pasquale Nigro, Andrea Chiappiniello, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 5, 2022
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as BiomarkersLorenzo Barba, Federico Paolini Paoletti, Giovanni Bellomo, et al.
Alzheimer'S Research & Therapy|May 22, 2025
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer's disease and Parkinson's diseaseLorenzo Gaetani, Giovanni Bellomo, Davide Chiasserini, et al.
Pageof 6